Lower magnesium level associated with new-onset diabetes and pre-diabetes after kidney transplantation

Cosio FG, Hickson LJ, Griffin MD, Stegall MD, Kudva Y (2008) Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transpl 8(3):593–599 Woodward RS, Schnitzler MA, Baty J et al (2003) Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transpl 3(5):590–598 Bee YM, Tan HC, Tay TL, Kee TY, Goh SY, Kek PC (2011) Incidence and risk factors for development of new-onset diabetes after kidney transplantation. Ann Acad Med Singap 40(4):160–167 Pham PT, Pham PM, Pham SV, Pham PA, Pham PC (2011) New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes. 4:175–186 Eckhard M, Schindler RA, Renner FC et al (2009) New-onset diabetes mellitus after renal transplantation. Transpl Proc. 41(6):2544–2545 Davidson J, Wilkinson A, Dantal J, et al (2003) New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75(10 Suppl):SS3–S24 Cosio FG, Kudva Y, van der Velde M et al (2005) New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 67(6):2415–2421 Boerner BP, Shivaswamy V, Desouza CV, Larsen JL (2011) Diabetes and cardiovascular disease following kidney transplantation. Curr Diabetes Rev 7(4):221–234 Hjelmesaeth J, Hartmann A, Leivestad T et al (2006) The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 69(3):588–595 Vincenti F, Friman S, Scheuermann E et al (2007) Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transpl 7(6):1506–1514 Drachenberg CB, Klassen DK, Weir MR et al (1999) Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 68(3):396–402 Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP (1996) Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest. 98(12):2786–2793 Tamura K, Fujimura T, Tsutsumi T et al (1995) Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 59(11):1606–1613 Lawrence MC, Bhatt HS, Watterson JM, Easom RA (2001) Regulation of insulin gene transcription by a Ca(2+)-responsive pathway involving calcineurin and nuclear factor of activated T cells. Mol Endocrinol 15(10):1758–1767 Grafton G, Baxter MA (1992) The role of magnesium in diabetes mellitus. A possible mechanism for the development of diabetic complications. J Diabetes Complicat 6(2):143–149 Tongyai S, Rayssiguier Y, Motta C, Gueux E, Maurois P, Heaton FW (1989) Mechanism of increased erythrocyte membrane fluidity during magnesium deficiency in weanling rats. Am J Physiol 257(2 Pt 1):C270–C276 Bugliani M, Masini M, Liechti R et al (2009) The direct effects of tacrolimus and cyclosporin A on isolated human islets: a functional, survival and gene expression study. Islets. 1(2):106–110 Tillmann FP, Quack I, Schenk A, Grabensee B, Rump LC, Hetzel GR (2012) Prevalence and risk factors of pre-diabetes after renal transplantation: a single-centre cohort study in 200 consecutive patients. Nephrol Dial Transpl 27(8):3330–3337 Porrini E, Moreno JM, Osuna A et al (2008) Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. Transplantation 85(8):1133–1138 Corica F, Corsonello A, Ientile R et al (2006) Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients. J Am Coll Nutr 25(3):210–215 Allegra A, Corica F, Ientile R et al (1998) Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplant recipients during cyclosporine and/or azathioprine treatment. Magnes Res 11(1):11–18 Guerrero-Romero F, Rascon-Pacheco RA, Rodriguez-Moran M, de la Pena JE, Wacher N (2008) Hypomagnesaemia and risk for metabolic glucose disorders: a 10-year follow-up study. Eur J Clin Invest 38(6):389–396 Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL, Brancati FL (1999) Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 159(18):2151–2159 Lima Mde L, Cruz T, Rodrigues LE et al (2009) Serum and intracellular magnesium deficiency in patients with metabolic syndrome—evidences for its relation to insulin resistance. Diabetes Res Clin Pract 83(2):257–262 Tosiello L (1996) Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med 156(11):1143–1148 Chaudhary DP, Sharma R, Bansal DD (2010) Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res 134(2):119–129 Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R (1993) Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 21(6 Pt 2):1024–1029 Takaya J, Higashino H, Kobayashi Y (2004) Intracellular magnesium and insulin resistance. Magnes Res 17(2):126–136 Guerrero-Romero F, Tamez-Perez HE, Gonzalez-Gonzalez G et al (2004) Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab. 30(3):253–258 Lopez-Ridaura R, Willett WC, Rimm EB et al (2004) Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 27(1):134–140 Rodriguez-Moran M, Guerrero-Romero F (2003) Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 26(4):1147–1152 Song Y, Manson JE, Buring JE, Liu S (2004) Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 27(1):59–65 Song Y, He K, Levitan EB, Manson JE, Liu S (2006) Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 23(10):1050–1056 Vannini SD, Mazzola BL, Rodoni L et al (1999) Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Transpl Int 12(4):244–249 Mazzola BL, Vannini SD, Truttmann AC et al (2003) Long-term calcineurin inhibition and magnesium balance after renal transplantation. Transpl Int 16(2):76–81 Nijenhuis T, Hoenderop JG, Bindels RJ (2004) Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 15(3):549–557 Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R (2009) Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transpl 9(9):2140–2149 American Diabetes A (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35 Suppl 1:S64–S71 Witkowski M, Hubert J, Mazur A (2011) Methods of assessment of magnesium status in humans: a systematic review. Magnes Res 24(4):163–180 Santos L, Rodrigo E, Pinera C et al (2010) Elevated serum gamma-glutamyltransferase and hypomagnesemia are not related with new-onset diabetes after transplantation. Transpl Proc 42(8):2914–2916 Osorio JM, Bravo J, Perez A, Ferreyra C, Osuna A (2010) Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes. Transpl Proc 42(8):2910–2913